The U.S. Food and Drug Administration (FDA) announced the approval of a generic version of Dapagliflozin on April 6, 2026. This approval, granted to sponsor Sandoz under Abbreviated New Drug Application (ANDA) 211312, makes a new formulation of the drug available to patients.
Background
Dapagliflozin is a well-established medication. The FDA's approval of ANDA 211312 signifies the availability of a generic alternative. An Abbreviated New Drug Application (ANDA) is submitted for generic drug products that are bioequivalent to an already approved brand-name drug. This process ensures that generic drugs have the same quality, strength, purity, and stability as their brand-name counterparts, and that they work in the same way and provide the same clinical benefit.
What this means
The FDA's approval of a generic Dapagliflozin is a significant development for patients, healthcare providers, and the broader healthcare system. Generic drugs typically offer a more cost-effective alternative to their brand-name counterparts, which can lead to increased patient access to necessary treatments and a reduction in overall healthcare expenditures. This approval by the FDA helps foster a competitive market for essential medications, potentially lowering costs and improving affordability for individuals who rely on Dapagliflozin for their medical conditions.
Source
The information regarding this approval was obtained from the U.S. Food and Drug Administration (FDA) database. The approval for Abbreviated New Drug Application (ANDA) 211312, concerning Dapagliflozin, was officially documented on April 6, 2026. Further details are accessible through the FDA's official website, specifically on accessdata.fda.gov.